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T-CELL activation results in the release or shedding of a
soluble form (45 kDa) of the cellular (55 kDa) low-affinity
interleukin-2 receptor (z-chain) (slL-2R). The present
study was performed to investigate if the serum
concentration of sIL-2R is a marker of disease activity in
patients with ulcerative colitis (UC), a chronic inflam-
matory bowel disease. Twenty-seven UC patients (about
half of them in remission) and 13 healthy volunteers
were studied, sIL-2R concentrations were measured by an
enzyme-linked immunosorbent assay, and significantly
elevated median sIL-2R values were found in clinically
active UC (150pg/ml; range 100-420), compared to
inactive UC (145pg/ml; range 110-255), and healthy
controls (110 pg/ml; range 80-165) (p < 0.01). There was
no correlation between sIL-2R concentrations and extent
of the disease. Due to the overlap of serum sIL-2R
concentrations between different disease stages and
controls, the general diagnostic value seems to be limited.
However, since slL-2R release is an IL-2 dependent
phenomenon, we conclude that the demonstration of
increased serum sIL-2R concentrations in UC suggests the
existence of an enhanced T-cell activation in vivo in this
disease. Further longitudinal studies are required to
elucidate if repeated measurements of sIL-2R levels
provide an additional way of monitoring UC disease
activity in individual patients.
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The etiology of ulcerative colitis (UC) is
unknown, but there is increasing evidence that
immunological factors, including T-cell mediated
immune functions, play a pathogenetic role in
inflammatory bowel disease (IBD). 1’2
T-cell proliferation and differentiation depend
primarily on the interplay between interleukin-2
(IL-2) and its specific receptor (IL-2R), which is
expressed on activated, but not on resting T-cells.>s
The biologically active, high-affinity IL-2R complex
consists of a high-affinity 75 kDa /J-chain, and a
low-affinity 55 kDa 0-chain. During activation, T-
cells release a soluble (45 kDa) form of the
low-affinity IL-2R z-chain (sIL-2R), which is
detectable by enzyme-linked immunosorbent assay
(ELISA) in serum and in inflamed gut tissue.
7-9
Circulating slL-2R levels may be of potential
clinical value for the disease activity assessment in
IBD,
1 and may also play a role in the regulation
of T-cell activation, because it binds free IL-2.
The aim of the present study was to evaluate if
serum concentration of sIL-2R is a marker of
disease activity in patients with different activity
stages of UC.
(C) 1993 Rapid Communications of Oxford Ltd
Materials and Methods
Patients: Twenty-seven patients (17 women, ten
men) (median age 40 years, range 19-77 years) with
UC,
2 were included in the study from the IBD
out-patient clinic of Herlev Hospital, together with
13 healthy volunteers (ten women and three men)
(median age 34 years, range 25-49 years).
The disease duration (time from diagnosis to
inclusion in the study) had a median of 6 years
(range 1-22 years). Eighteen patients (67%) had
distal (proctosigmoid) disease, and nine (33%) were
more extensively affected.
Disease activity was assessed on an ordered scale
from 1 (remission) to 4 (severe activity).
13 About
one half of the patients (n 13; 48%) were in
remission, and about one half (n 14; 52%) had
moderately active disease (grade 3). Only two (14%)
UC patients with active disease received drugs
(sulphasalazine or 5-aminosalicylic acid). Con-
sequently none received glucocorticoid or immuno-
suppressive treatment at the time of blood sample
collection.
The study was approved by the Scientific Ethical
Committee of the Copenhagen County. In accor-
dance with the Second Helsinki Declaration,
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informed consent was obtained from all patients
and healthy volunteers before entering the study.
sIL-2R: Serum sIL-2R concentrations were mea-
sured as described in detail previously
1 using a
sandwich ELISA (T Cell Sciences, MA, USA). The
ELISA incorporates a primary monoclonal anti-
body against the Tac-epitope,
14 and a second
monoclonal antibody (7G7/B6), which binds to an
IL-2R epitope (z-chain) different from that of
anti-TAC and IL-2.5 Units of slL-2R were
calculated from a standard curve. Previous studies
have shown 1 ELISA unit to be equivalent to 0.3 pg
purified receptor.
6 The coefficient of variation was
less than 0.10.
Statistics: Variance analysis of unpaired data for
trend was performed by the Jonckheere-Terpstra
test, which is one-tailed; unpaired data by the
Mann-Whitney test (two-sided). The significance
limit for p values was less than 5%.
Results
The serum sIL-2R concentrations were sig-
nificantly increased in UC patients (median 150
pg/ml, range 100-420) compared with controls
(median 110 pg/ml, range 80-165) (p < 0.02).
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FIG. 1. Serum concentrations (pg/ml) of soluble interleukin-2 receptors
(slL-2R) in 27 patients with ulcerative colitis (UC) (14 with active
disease (A), and 13 in remission (R)) and 13 healthy volunteers (C).
Bars represent median values.
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FIG. 2. Serum concentrations (pg/ml) of slL-2R among 27 patients with
ulcerative colitis (UC) (18 with proctosigmoiditis (P) and nine with
more extensive colitis (E)). Bars represent median values. (NS- not
significant.)
concentration was significantly higher in UC
patients with active disease (150 pg/ml), compared
with those in remission (145 pg/ml), and controls
(110pg/ml) (p < 0.01) according to a variance
analysis.
There was no significant difference in slL-2R
concentrations between patients with proctosigmoi-
ditis (median 140pg/ml) and those with more
extensive colitis (median 155 pg/ml) (p 0.19),
(Fig. 2).
Discussion
IL-2 is a T-cell-derived cytokine which plays a
key role in the regulation of T-lymphocyte
functions. Peripheral blood lymphocyte activation
is a prominent feature of many putative auto-
immune diseases,
17<9 and sIL-2R has been proposed
as a simple method of assessing in vivo T- (and B-)
cell activation.2 For instance, serum sIL-2R
concentrations correlate with disease activity in
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rheumatoid arthritis, atopic eczema, Behets dis-
ease,
21-23 systemic lupus
24 and chronic autoimmune
hepatitis,
is
As regards IBD, there is an increased infiltration
of lymphocytes in the inflamed lamina propria as
compared to normal bowel.2’26 Both peripheral and
mucosal T-cells from patients with active IBD
express IL-2R on their surfaces, whereas in the
normal colon only a few lymphocytes stain with the
antibody to the low-aflqnity IL-2R (Tac-anti-
gen).
27
A number of studies in patients with CD have
shown a markedly accelerated production of sIL-iR
by peripheral blood mononuclear cells which
corresponds to the consistent demonstration of
significantly increased serum slL-2R levels in active,
but not in inactive disease stages.9’28-3 There seems,
however, to be a differential expression of cellular
IL-iR in patients with CD and UC
31 which has been
proposed to distinguish between the two disorders.
Thus, the IL-2R (CD25) bearing cells are abundant
in the submucosa in CD but to a lesser extent in
UC. Furthermore, the CD25 + cells in CD comprise
58-88% CD3+, CD4+, and CD8--, indicating
that they are T-cells, whereas in UC the CD25 +
cells comprise more than 80% CD3--, CD4 +, and
HLA-DR+, indicating that they are macro-
phages.
31 In two previous studies on circulating
slL-2R concentrations in patients with active UC,
nearly all patients studied received either an oral
glucocorticoid, azathioprine, sulphasalazine/5-
aminosalicylic acid, or combinations thereof.29’32
Although these drugs may interfere with different
steps in the IL-2 dependent pathway of immune
activation, 1’33 significantly higher serum levels of
sIL-2R were found in patients with active UC,
which is in accordance with the present findings,
based on mainly untreated patients. Consequently,
ongoing treatment with these drugs seems to have
little influence on slL-2R levels, provided that these
patients have active disease.
Lamina propria lymphocytes from UC patients
release significantly less amounts of sIL-2R in vitro
as compared with controls. 32’34 This finding is
somewhat difficult to reconcile with the repeated
demonstration of increased sIL-2R levels in tissue
homogenates from the same patient category, 19’29
but it illustrates that the precise cellular source of
sIL-2R in UC is unknown. Apart from confirming
elevated sIL-2R levels in patients with active and
mainly untreated UC, the present study also shows
that even UC patients in remission have sig-
nificantly elevated serum sIL-2R levels.
There was no difference between circulating
sIL-iR levels in patients with proctosigmoiditis and
those with more extensive colitis, suggesting an
equal degree of immune activation. This may be in
accordance with the clinical experience that the
intensity of immunosuppressive treatment should
be chosen on the basis of the severity rather than
the extent of the disease.
35
The biological role of raised sIL-iR levels is yet
unknown, sIL-2R may have an immunoregulatory
role by competing with the IL-iR complex on cell
surfaces for free IL-2, thus facilitating a down-
regulation of the immune response.
11 Accordingly,
when blood mononuclear cells from patients with
active IBD are stimulated with IL-2 in vitro, the
result is an increased cellular expression of low
aflqnity IL-2R which, apart from binding free IL-2,
also has been proposed to represent biologically
active binding sites. 36
The release of sIL-2R is an IL-2 dependent
phenomenon.
37 We conclude that the demonstra-
tion of increased serum slL-2R levels in patients
with UC suggests an enhanced T-cell activation in
this disorder. However, the overlaps between
different disease stages, and between patients and
controls, limit the general diagnostic value of this
measure. Longitudinal studies are required to
elucidate a possible role of serum sIL-2R as an
additional marker of disease activity in individual
patients who act as their own controls.
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